Evidence map›Paper›PMID 30090207›Full record

ArticleAvicenna journal of medical biotechnology

A Feasibility Study to Evaluate

Mahdi Karimi, Farida Behzadian, Hamideh Rouhaninejad, Sanaz Yari

Open access · greenAbstract read
In one paragraph

Article in Avicenna journal of medical biotechnology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Animals : an open access journal from MDPI · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Mahdi KarimiDepartment of Molecular Genetics, Research Centre for Biosciences and Biotechnology, Malek-Ashtar University of Technology, Tehran, Iran.
Farida BehzadianDepartment of Molecular Genetics, Research Centre for Biosciences and Biotechnology, Malek-Ashtar University of Technology, Tehran, Iran.
Hamideh RouhaninejadDepartment of Molecular Genetics, Research Centre for Biosciences and Biotechnology, Malek-Ashtar University of Technology, Tehran, Iran.
Sanaz YariDepartment of Molecular Genetics, Research Centre for Biosciences and Biotechnology, Malek-Ashtar University of Technology, Tehran, Iran.
Malek Ashtar University of Technology · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBiosynthetic teriparatide (1-34) (TPD) is a N-terminally truncated version of human parathyroid hormone (hPTH). The recombinant form of this polypeptide has been expressed in

methodsA codon optimized gene containing TPD open reading frame carrying enterokinase site in its upstream was fully synthesized. According to our cloning scheme, this synthetic polynucleotide was used as a template for PCR amplification using engineered primers in such a way that a polyhistidin tag was added in frame to the upstream of the amplicon as well as two restriction sites at its ends. The resulted amplicon, a cassette containing His-tag, enterokinase site and TPD, from 5' to 3', was cloned into pTZ57R/T vector and subjected to sequencing.The cassette was then subcloned into pHT43 shuttle vector and transformed into

resultsThe accuracy of construction of pHT43-TPD was confirmed by sequencing and restriction map analyses. SDS-PAGE and western blotting results showed that the recombinant fusion form of hPTH was successfully expressed and secreted into cytoplasm and extracellular medium.

conclusionTPD may be successfully expressed and secreted in

Indexed as

Bacillus subtilishPTHTeriparatide

Identifiers

PMID30090207
PMCPMC6064005
OpenAlexW2890255923

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.